


What is claimed is ;


1. A cell activator comprising a glycosphingolipid having a structure represented by the following formula (1):

formula (1)



wherein R¹ represents the following formula (1-1):

formula (1-1)




wherein R³ represents alkyl or alkenyl and R⁴ represents alkyl; and

R² represents hydrogen, or α -galactose, α -glucose, α -mannose, α -glucosamine, β -glucosamine or a combination thereof.


2. A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R⁵ represents R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, or R⁷⁸; and R⁶ represents hydrogen, R⁶², R⁶³, R⁶⁴, or R⁶⁵:


R⁵¹ :




R⁵² :




R⁵³ :




R⁵⁴ :




R⁵⁵ :




R⁵⁶ :




R⁵⁷ :




R⁵⁸ :




R⁵⁹ :




R⁷⁰ :




R⁷¹ :




R⁷² :




R⁷³ :




R⁷⁴ :




R⁷⁵ :




R⁷⁶ :




R⁷⁷ :




R⁷⁸ :




R⁶² :




R⁶⁴ :



R⁶³ :



R⁶⁵ :



3. A method of activating NKT cell which comprises administering the cell activator according to claim 1 to a mammal.

4. A method of activating NKT cell which comprises administering the cell activator according to claim 2 to a mammal.

5. A method of accelerating IL-4 production which comprises administering the cell activator according to claim 1 to a mammal.

6. A method of accelerating IL-4 production which comprises administering the cell activator according to claim 2 to a mammal.

7. A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 1 to a mammal.

8. A method of accelerating IFN- γ production which comprises administering the cell activator according to claim 2 to a mammal.

9. A method of activating dendritic cell which comprises administering the cell activator according to claim 1 to a mammal.

10. A method of activating dendritic cell which comprises administering the cell activator according to claim 2 to a mammal.

11. A method of accelerating IL-12 production which comprises administering the cell activator according to claim 1 to a mammal.

12. A method of accelerating IL-12 production which comprises administering the cell activator according to claim 2 to a mammal.

13. A method of accelerating IL-10 production which comprises administering the cell activator according to claim 1 to a mammal.

14. A method of accelerating IL-10 production which comprises administering the cell activator according to claim 2 to a mammal.

15. A method of activating NK cell which comprises administering the cell activator according to claim 1 to a mammal.

16. A method of activating NK cell which comprises administering the cell activator according to claim 2 to a mammal.

17. A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 1 to a mammal.

18. A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 2 to a mammal.

19. A method for treatment or prophylaxis of allergy comprises

administering the cell activator according to claim 1 to a mammal.

20. A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 2 to a mammal.

21. A method of enhancing resistance to infection which comprises administering the cell activator according to claim 1 to a mammal.

22. A method of enhancing resistance to infection which comprises administering the cell activator according to claim 2 to a mammal.

23. A method of inhibiting viral activity which comprises administering the cell activator according to claim 1 to a mammal.

24. A method of inhibiting viral activity which comprises administering the cell activator according to claim 2 to a mammal.

25. A method of accelerating IL-6 production which comprises administering the cell activator according to claim 1 to a mammal.

26. A method of accelerating IL-6 production which comprises administering the cell activator according to claim 2 to a mammal.

27. A method of accelerating NO production which comprises administering the cell activator according to claim 1 to a mammal.

28. A method of accelerating NO production which comprises administering the cell activator according to claim 2 to a mammal.